WS #15043

Geopolitical risk is the dominant market driver, with the Middle East escalation thesis intensifying as hopes for a US-Iranian blockade resolution fade. Oil prices are rising above $107, reflecting supply chain anxiety over the Strait of Hormuz, while global equities are broadly selling off. This represents a clear escalation from the previous window, where the rejection of sanctions relief was the primary catalyst; the market is now pricing in a prolonged disruption rather than a temporary spike. In the technology sector, a divergence is emerging between hardware infrastructure and software giants. BlackRock's pivot toward 'physical AI' is driving capital toward semiconductor and data center infrastructure names like Micron (MU) and Vertiv (VRT), while Google faces regulatory headwinds in the EU. Meanwhile, the biotech sector is seeing localized bullish momentum driven by major M&A activity, specifically AstraZeneca's investment in Summit Therapeutics. Macro signals remain mixed but lean hawkish. The RBA's rate hike to a 15-year high reinforces the global tightening cycle, although some fixed-income strategists argue the bond selloff is overdone. Corporate earnings and contract wins, such as Fluor's LNG Canada deal, provide isolated pockets of strength, but the overarching narrative is one of cost pressure and geopolitical uncertainty weighing on growth assets.